S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
These 5 Tech Stocks Have 10x Potential (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:AKRO

Akero Therapeutics - AKRO Price Target & Analyst Ratings

$45.69
-0.81 (-1.74%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$45.64
$46.79
50-Day Range
$25.91
$46.50
52-Week Range
$7.52
$48.24
Volume
538,509 shs
Average Volume
640,789 shs
Market Capitalization
$2.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.75

Akero Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$44.75
-2.06% Downside
High Prediction$64.00
Average Prediction$44.75
Low Prediction$25.00
TypeCurrent
12/2/21 to 12/2/22
1 Month Ago
11/2/21 to 11/2/22
3 Months Ago
9/3/21 to 9/3/22
1 Year Ago
12/2/20 to 12/2/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$44.75$41.75$43.67$52.33
Predicted Upside-2.06% Downside50.37% Upside73.97% Upside83.78% Upside
Get Akero Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.


AKRO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akero Therapeutics Stock vs. The Competition

TypeAkero TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside-2.06% Downside575.39% Upside11.38% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
83
60.14%
Underperform Votes
55
39.86%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$30.00 ➝ $40.00+0.98%
11/7/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$62.00 ➝ $64.00+66.32%
9/13/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform$10.00 ➝ $50.00+72.12%
9/13/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$14.00 ➝ $25.00-9.09%
9/10/2021Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$40.00+62.34%
3/23/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Yee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$48.00+41.01%
3/17/2021Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetPositive ➝ Buy$79.00 ➝ $81.00+155.52%
2/26/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$54.00+81.09%
7/1/2020JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$28.00 ➝ $41.00+64.53%
(Data available from 12/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












AKRO Price Target - Frequently Asked Questions

What is Akero Therapeutics's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Akero Therapeutics stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for AKRO. The average twelve-month price prediction for Akero Therapeutics is $44.75 with a high price target of $64.00 and a low price target of $25.00. Learn more on AKRO's analyst rating history.

Do Wall Street analysts like Akero Therapeutics more than its competitors?

Analysts like Akero Therapeutics more than other Medical companies. The consensus rating for Akero Therapeutics is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how AKRO compares to other companies.

Do MarketBeat users like Akero Therapeutics more than its competitors?

MarketBeat users like Akero Therapeutics less than other Medical companies. 60.14% of MarketBeat users gave Akero Therapeutics an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Akero Therapeutics being upgraded by Wall Street analysts?

Over the previous 90 days, Akero Therapeutics's stock had 1 upgrade by analysts.

Does Akero Therapeutics's stock price have much upside?

According to analysts, Akero Therapeutics's stock has a predicted upside of 29.56% based on their 12-month price targets.

What analysts cover Akero Therapeutics?

Akero Therapeutics has been rated by Evercore ISI, HC Wainwright, Morgan Stanley, and Raymond James in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:AKRO) was last updated on 12/2/2022 by MarketBeat.com Staff